OMACOR

Pronova BioPharma is a Norwegian pharmaceutical company that pioneered the development of highly concentrated omega-3 fatty acids for medicinal use. The company is most famous for creating Omacor, which was the first prescription omega-3 drug to receive regulatory approval globally for the treatment of hypertriglyceridemia. Marketed as Lovaza in the United States through a partnership with GSK, the product became a blockbuster treatment for cardiovascular health. Pronova's core expertise lies in its sophisticated manufacturing processes for purifying marine oils into pharmaceutical-grade ethyl esters. In 2013, the company was acquired by BASF for approximately 825 million USD, integrating its operations into BASF's Nutrition & Health division. The company's legacy continues through its specialized production facilities in Norway, which remain a global hub for high-purity omega-3 active pharmaceutical ingredients.